Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) regularly issues news updates about its progress in gene therapies for blindness diseases, making its news flow particularly relevant for investors and observers of the ophthalmic biotechnology space. The company’s announcements often cover clinical trial milestones, licensing agreements, financing transactions, and participation in industry and investor conferences.
A major focus of Ocugen’s recent news has been its modifier gene therapy platform and associated programs. Updates include Phase 1, Phase 2, and Phase 2/3 data for investigational products such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease. Press releases describe safety and exploratory efficacy findings, such as lesion growth reduction and visual function outcomes, as well as plans for future regulatory submissions.
Ocugen’s news stream also highlights business development and capital markets activity. Examples include an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, registered direct offerings of common stock and warrants, and updates on cash runway and financial results. In addition, the company frequently announces webcasts and conference calls to discuss quarterly results, business updates, and key clinical data readouts.
Another recurring theme in Ocugen’s news is its presence at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, NobleCon, and rare disease–focused events. These items outline presentation topics, panel participation, and the company’s messaging around its goal of advancing multiple Biologics License Application (BLA) filings within a defined timeframe.
Investors and followers of OCGN news can use this page to monitor clinical trial progress, licensing developments, financing events, and strategic communications as Ocugen advances its gene therapy programs for major retinal diseases.
Ocugen has signed a non-binding letter of intent to acquire a dormant vaccine manufacturing site in Belleville, Ontario from Liminal BioSciences. This facility aims to enhance Ocugen's manufacturing and R&D capabilities, particularly for its COVID-19 vaccine candidate, COVAXIN™ (BBV152). The renovated site will serve as a hub for breakthrough gene therapies and is expected to stimulate regional economic growth and job creation in Ontario. The acquisition, however, is subject to due diligence and final agreements, with no assurance of completion.
Ocugen, Inc. (NASDAQ: OCGN) announces the appointment of Dr. Nirdosh Jagota as Senior Vice President of Regulatory Affairs. He brings 30 years of experience in the biopharmaceutical sector, previously serving at Arcturus Therapeutics and holding senior roles at major companies like Genentech and Pfizer. Dr. Jagota is tasked with overseeing regulatory strategies for Ocugen’s gene therapy and vaccine development. His extensive background includes the successful approval of over 30 vaccines and therapeutics. The company aims to enhance its regulatory capabilities and expedite product commercialization.
Ocugen, Inc. (NASDAQ: OCGN) announced the approval of stock options and restricted stock units (RSUs) totaling 787,268 shares and 217,681 shares, respectively, for three new hires. The grants were made on January 10 and January 17, 2022, as incentives for employment in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with exercise prices of $4.32 and $4.25. They will vest in equal installments over three years, contingent upon continued service. Ocugen focuses on gene therapies for blindness diseases and the COVAXIN vaccine for COVID-19.
Ocugen, Inc. (NASDAQ: OCGN) and Bharat Biotech announced that the booster dose of their candidate vaccine, COVAXIN™ (BBV152), generated strong neutralizing antibody responses against the Omicron and Delta variants. The study showed that 100% of serum samples neutralized the Delta variant, while over 90% neutralized Omicron. These findings suggest COVAXIN™ is a viable option amid the evolving COVID-19 pandemic. The results will be published on medRXiv soon. COVAXIN™ is currently in review for emergency use authorization in the U.S. among children aged 2-18 years.
Ocugen (NASDAQ: OCGN) announced positive Phase 2 results for its COVID-19 vaccine candidate, COVAXIN™, showcasing significant increases in neutralizing titers after a booster dose. Participants aged 12-64 exhibited over a 10-fold boost in neutralizing antibodies against multiple variants six months post-second dose. Additionally, the analysis reported persistent immune responses and no serious adverse events. COVAXIN™ is currently authorized in 17 countries, with efficacy against the Omicron variant under study. These findings support the potential of COVAXIN™ as a durable vaccine option amid evolving COVID-19 variants.
Ocugen, a biopharmaceutical company (NASDAQ: OCGN), announced its participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. Dr. Shankar Musunuri, CEO and Co-Founder, will present on January 10, 2022, focusing on COVAXIN™, an investigational COVID-19 vaccine under FDA review, and the innovative OCU400 therapy, which begins clinical trials in Q1 2022. The presentation will be available on-demand starting at 7:00 AM ET.
For registration, visit: here.
Ocugen, Inc. (Nasdaq: OCGN) announced successful results from a Phase 2/3 trial of COVAXIN™ in children aged 2-18, showing robust antibody responses similar to adults and a favorable safety profile. The study demonstrated a strong neutralizing antibody response with no serious adverse events reported. Following these results, Ocugen submitted a pediatric Emergency Use Authorization (EUA) application in the U.S. on November 5, 2021. The findings come amid rising COVID-19 cases globally, highlighting COVAXIN's potential to enhance pediatric vaccination efforts.
Ocugen, Inc. (NASDAQ: OCGN) announced on December 20, 2021, that its Compensation Committee has approved stock options and restricted stock units (RSUs) for a new employee. The stock options total 6,750 shares with an exercise price of $5.02, reflecting the closing price on the grant date of December 16, 2021. The RSUs cover 1,150 shares and both grants vest over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment, supporting Ocugen's focus on gene therapies and COVID-19 vaccine development.
Ocugen announced positive findings from a third-party study of its COVID-19 vaccine candidate, COVAXIN™ (BBV152), published on medRxiv. The study revealed that immune responses from vaccinated individuals showed antibody levels comparable to those from natural infections. Additionally, T and B cell memory persisted for at least six months. The findings suggest that COVAXIN™ may be effective against current and future COVID-19 variants. Ongoing studies aim to evaluate its efficacy against the Omicron variant.
Ocugen (OCGN) has announced that the FDA accepted their IND application to initiate a first-in-human trial for OCU400, a gene therapy targeting retinitis pigmentosa due to NR2E3 and RHO gene mutations. The study aims to enroll patients starting Q1 2022. OCU400 has the potential to address numerous mutations with a single therapy, differing from traditional methods that target individual mutations. This gene therapy has received multiple orphan drug designations, indicating its potential to treat a variety of genetic retinal diseases.